Streetbeat News

ABSI

Absci Corporation

https://www.absci.com

Industry

Biotechnology

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Open

3.73

Mkt cap

424M

Volume

2.4M

High

3.76

P/E Ratio

-3.97

52-wk high

6.72

Low

3.51

Div yield

N/A

52-wk low

2.45

Absci Corporation held its Q3 2024 earnings call, discussing financial performance and business updates. Key participants included company executives and analysts from various securities firms.

Portfolio Pulse from

November 12, 2024 | 3:30 pm

Absci Corporation (ABSI) reported a Q3 loss of $0.24 per share, missing the Zacks Consensus Estimate of a $0.19 loss. This matches the loss per share from the previous year.

Portfolio Pulse from

November 12, 2024 | 3:00 pm

Absci has reported its third quarter 2024 financial and operating results, highlighting the successful delivery of AI-designed antibody sequences to AstraZeneca, marking the first milestone in their collaboration.

Portfolio Pulse from

November 12, 2024 | 12:45 pm

Absci Corporation (Nasdaq: ABSI) will host its 2024 R&D Day on December 12th in New York City, focusing on its generative AI drug creation capabilities.

Portfolio Pulse from

November 07, 2024 | 1:15 pm

Absci Corporation and Twist Bioscience Corporation have announced a collaboration to design a novel therapeutic using generative AI. This partnership combines Absci's expertise in AI-driven drug creation with Twist's synthetic DNA technology.